Shubh Goel, VP, Global Franchise Head, Bispecifics at AstraZeneca, shared on LinkedIn:
“September is Mesothelioma Awareness Month, an important time for more than 30,000 people worldwide living with this aggressive form of cancer that affects the lining of the lungs. It is crucial that we do our part in raising awareness for this disease, which because of its rarity, has long gone under researched. Lack of new treatment options has caused decades of low survival rates and that needs to change.
At AstraZeneca, we are dedicated to exploring areas of high unmet need and researching potential approaches. I am proud to work alongside colleagues who share a passion for improving outcomes for rare cancers like mesothelioma, as we continue to seek new insights and possibilities.”
More posts featuring Shubh Goel.